Cargando…

Successful treatment of oral Crohn's disease by anti-TNF-alpha dose escalation - a case report

BACKGROUND: Crohn’s Disease (CD) is typically characterized by abdominal symptoms, however, besides gastrointestinal symptoms, CD patients may suffer from extraintestinal manifestations which are far less common and medical treatment can be challenging. CASE PRESENTATION: We report about a 34-year-o...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bokemeyer, Arne, Tentrop, Nicolas, Barth, Peter J., Lenze, Frank, Hengst, Karin, Kleinheinz, Johannes, Bettenworth, Dominik
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2018
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6007058/ https://www.ncbi.nlm.nih.gov/pubmed/29914414 http://dx.doi.org/10.1186/s12876-018-0818-7

Ejemplares similares

Crohn’s Disease Patients in Remission Display an Enhanced Intestinal IgM(+) B Cell Count in Concert with a Strong Activation of the Intestinal Complement System
por: Preisker, Sophie, et al.
Publicado: (2019)

Endoscopic Radiofrequency Ablation Prolongs Survival of Patients with Unresectable Hilar Cholangiocellular Carcinoma - A Case-Control Study
por: Bokemeyer, Arne, et al.
Publicado: (2019)

Giant cell arteritis exclusively detected by (18)F-fluorodeoxyglucose positron emission tomography: a case report
por: Brückner, Markus, et al.
Publicado: (2014)

Medical therapy of stricturing Crohn’s disease: what the gut can learn from other organs - a systematic review
por: Bettenworth, Dominik, et al.
Publicado: (2014)

Ustekinumab dose escalation improves clinical responses in refractory Crohn’s disease
por: Haider, Syedreza A., et al.
Publicado: (2020)

Assessment of Crohn’s disease-associated small bowel strictures and fibrosis on cross-sectional imaging: a systematic review
por: Bettenworth, Dominik, et al.
Publicado: (2019)

MicroRNA-320a Monitors Intestinal Disease Activity in Patients With Inflammatory Bowel Disease
por: Cordes, Friederike, et al.
Publicado: (2020)

Differential regulation of JAK/STAT-signaling in patients with ulcerative colitis and Crohn’s disease
por: Cordes, Friederike, et al.
Publicado: (2020)

Efficacy and Safety of Escalation of Adalimumab Therapy to Weekly Dosing in Pediatric Patients with Crohn's Disease
por: Dubinsky, Marla C., et al.
Publicado: (2016)

Cost savings of anti-TNF therapy using a test-based strategy versus an empirical dose escalation in Crohn's disease patients who lose response to infliximab
por: Roblin, Xavier, et al.
Publicado: (2015)

Dose Escalation Patterns of Advanced Therapies in Crohn’s Disease and Ulcerative Colitis: A Systematic Literature Review
por: Panaccione, Remo, et al.
Publicado: (2023)

Evaluation of changes in intestinal microbiota in Crohn’s disease patients after anti-TNF alpha treatment
por: Sanchis-Artero, Laura, et al.
Publicado: (2021)

Treatment escalation and de-escalation decisions in Crohn’s disease: Delphi consensus recommendations from Japan, 2021
por: Nakase, Hiroshi, et al.
Publicado: (2023)

Relationship between Vagal Tone, Cortisol, TNF-Alpha, Epinephrine and Negative Affects in Crohn’s Disease and Irritable Bowel Syndrome
por: Pellissier, Sonia, et al.
Publicado: (2014)

Target-Specific Fluorescence-Mediated Tomography for Non-Invasive and Dynamic Assessment of Early Neutrophil Infiltration in Murine Experimental Colitis
por: Nowacki, Tobias M., et al.
Publicado: (2019)

Antitumor Necrosis Factor-Alpha (TNF-α) Infliximab-Induced Pleural Effusion and Pericarditis in Crohn's Disease
por: Fonseca, Ashley, et al.
Publicado: (2021)

Anti-TNF Therapy in Crohn’s Disease
por: Adegbola, Samuel O., et al.
Publicado: (2018)

Effect of elemental diet combined with infliximab dose escalation in patients with Crohn's disease with loss of response to infliximab: CERISIER trial
por: Hisamatsu, Tadakazu, et al.
Publicado: (2018)

Rare and Serious Adverse Effects of Anti-Tumor Necrosis Factor-Alpha (TNF-α) Agents in Crohn’s Disease
por: Kim, Sun, et al.
Publicado: (2021)

Quantitative Phase Imaging Using Digital Holographic Microscopy to Assess the Degree of Intestinal Inflammation in Patients with Ulcerative Colitis
por: Bokemeyer, Arne, et al.
Publicado: (2023)

Quantitative Phase Imaging Using Digital Holographic Microscopy Reliably Assesses Morphology and Reflects Elastic Properties of Fibrotic Intestinal Tissue
por: Bokemeyer, Arne, et al.
Publicado: (2019)

Oral carvedilol in escalating doses in the acute treatment of atrial fibrillation
por: Chitrapu, Ravi Venkatachelam, et al.
Publicado: (2014)

Successful Treatment of Oral Crohn’s Disease by Ustekinumab
por: Jukema, Jelmer B, et al.
Publicado: (2020)

Dose escalation of radiotherapy in unresectable extrahepatic cholangiocarcinoma
por: Elganainy, Dalia, et al.
Publicado: (2018)

Use of Anti-TNF Alpha Blockers Can Reduce Operation Rate and Lead to Growth Gain in Pediatric Crohn's Disease
por: Woo, Min Hyung, et al.
Publicado: (2019)

Efficacy of enteral nutrition in patients with Crohn’s disease on maintenance anti-TNF-alpha antibody therapy: a meta-analysis
por: Hirai, Fumihito, et al.
Publicado: (2019)

Dose escalation of a curcuminoid formulation
por: Lao, Christopher D, et al.
Publicado: (2006)

What does a modified-Fibonacci dose-escalation actually correspond to?
por: Penel, Nicolas, et al.
Publicado: (2012)

Incoherent dose-escalation in phase I trials using the escalation with overdose control approach
por: Wheeler, Graham M.
Publicado: (2016)

Efficacy and safety of tofacitinib dose de‐escalation and dose escalation for patients with ulcerative colitis: results from OCTAVE Open
por: Sands, Bruce E., et al.
Publicado: (2019)

In vitro inhibition of HUVECs by low dose methotrexate – insights into oral adverse events
por: Annussek, Tobias, et al.
Publicado: (2014)

Adalimumab Dose-Escalation Therapy Is Effective in Refractory Crohn's Disease Patients with Loss of Response to Adalimumab, Especially in Cases without Previous Infliximab Treatment
por: Suzuki, Taketo, et al.
Publicado: (2019)

Baseline tumour necrosis factor alpha levels predict the necessity for dose escalation of infliximab therapy in patients with rheumatoid arthritis
por: Takeuchi, Tsutomu, et al.
Publicado: (2011)

Radiation treatment planning with embedded dose escalation
por: Hrinivich, William T., et al.
Publicado: (2019)

The role of biological dose-escalation for pancreatic cancer
por: Bruynzeel, Anna M.E., et al.
Publicado: (2019)

National trends in radiation dose escalation for glioblastoma
por: Wegner, Rodney E., et al.
Publicado: (2019)

Dose-escalating ruxolitinib for refractory hemophagocytic lymphohistiocytosis
por: Song, Yue, et al.
Publicado: (2023)

De-escalation of biological therapy in inflammatory bowel disease patients following prior dose escalation
por: Thomas, Pepijn W. A., et al.
Publicado: (2022)

Seven Weeks of High-Dose Vitamin D Treatment Reduces the Need for Infliximab Dose-Escalation and Decreases Inflammatory Markers in Crohn’s Disease during One-Year Follow-Up
por: Bendix, Mia, et al.
Publicado: (2021)

Toxicity of dose-escalated radiotherapy up to 84 Gy for prostate cancer
por: Rosenbrock, Johannes, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_e0fr0ies3fu5tbpor5mgog4qkc